As of November 7, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Context Therapeutics Inc. The largest reported stake is Avidity Partners Management LP's, at 8.7%. 16 filings are on record since August 14, 2025 (Schedule 13G/A, May 12, 2026).
Sell to companies like Context Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: MPM BioImpact LLC · Sole voting: 1,299,046 · Shared voting: 0 · Sole dispositive: 1,299,046 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Blue Owl Capital Holdings LP · Sole voting: 2,934,015 · Shared voting: 0 · Sole dispositive: 2,934,015 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-12
- · Reporting person: Octagon Capital Advisors LP · Sole voting: 0 · Shared voting: 3,050,000 · Sole dispositive: 0 · Shared dispositive: 3,050,000 · SCHEDULE 13G/A, 2026-07-31
- · Reporting person: BlackRock, Inc. · Sole voting: 6,087,367 · Shared voting: 0 · Sole dispositive: 6,169,250 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-27
- · Holder: Great Point Partners, LLC · Percent: 2.44% · SCHEDULE 13G/A
Context Therapeutics Inc. has 16 Schedule 13D or 13G filings on record since 2025-08-14. 3 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Avidity Partners Management LP | 8.7% | 8,302,808 | SCHEDULE 13G/A, 2026-05-12 | 2026-03-31 |
| Soleus Capital Master Fund, L.P. | 7.6% | 6,963,141 | SCHEDULE 13G/A, 2026-05-08 | 2026-03-31 |
| BlackRock, Inc. | 6.7% | 6,169,250 | SCHEDULE 13G, 2026-07-27 | 2026-06-30 |
| Octagon Capital Advisors LP | 3.3% | 3,050,000 | SCHEDULE 13G/A, 2026-07-31 | 2026-06-30 |
| Blue Owl Capital Holdings LP | 3.19% | 2,934,015 | SCHEDULE 13G/A, 2026-08-12 | 2026-06-30 |
| Great Point Partners, LLC | 2.44% | 2,238,496 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| MPM BioImpact LLC | 1.4% | 1,299,046 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
Holding shares or following this stake? See who's behind Context Therapeutics Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Context Therapeutics Inc. and the records around it.
Context Therapeutics Inc. elsewhere on the record
Companies that share a holder
- MPM BioImpact LLC also filed stake reports on 4 other companies: Climb Bio, Inc. (Aug 2026), DBV TECHNOLOGIES S.A. (Aug 2026), Forte Biosciences, Inc. (May 2026)
- Avidity Partners Management LP also filed stake reports on 5 other companies: Immunic, Inc. (Apr 2026), Perspective Therapeutics, Inc. (Mar 2026), Scynexis, Inc. (Feb 2026)
- Octagon Capital Advisors LP also filed stake reports on 8 other companies: Precision BioSciences, Inc. (Nov 2026), Corbus Pharmaceuticals Holdings, Inc. (May 2026), Dianthus Therapeutics, Inc. /DE/ (May 2026)
Watch Context Therapeutics Inc.
Get an email when Context Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Context Therapeutics Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Context Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Context Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 6,087,367 | 0 | 6,169,250 | 0 | SCHEDULE 13G, 2026-07-27 |
| Octagon Capital Advisors LP | 0 | 3,050,000 | 0 | 3,050,000 | SCHEDULE 13G/A, 2026-07-31 |
| Octagon Investments Master Fund LP | 0 | 3,050,000 | 0 | 3,050,000 | SCHEDULE 13G/A, 2026-07-31 |
| Ting Jia | 0 | 3,050,000 | 0 | 3,050,000 | SCHEDULE 13G/A, 2026-07-31 |
| Blue Owl Capital Holdings LP | 2,934,015 | 0 | 2,934,015 | 0 | SCHEDULE 13G/A, 2026-08-12 |
| MPM BioImpact LLC | 1,299,046 | 0 | 1,299,046 | 0 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Context Therapeutics Inc. by CUSIP 21077P108 and gives its principal executive office as 2001 MARKET STREET, SUITE 3915 UNIT #15, PHILADELPHIA, PA 19103 (SCHEDULE 13G/A, 2026-08-14).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Avidity Partners Management LP | 9.9% | SCHEDULE 13G/A |
| 2025-08-14 | Great Point Partners, LLC | 5.22% | SCHEDULE 13G/A |
| 2025-11-14 | Avidity Partners Management LP | 9.9% | SCHEDULE 13G/A |
| 2025-11-14 | Great Point Partners, LLC | 5.22% | SCHEDULE 13G/A |
| 2026-02-03 | Soleus Capital Master Fund, L.P. | 5.2% | SCHEDULE 13G |
| 2026-02-17 | Great Point Partners, LLC | 5.1% | SCHEDULE 13G/A |
| 2026-02-17 | MPM BioImpact LLC | 11.6% | SCHEDULE 13G/A |
| 2026-05-08 | Soleus Capital Master Fund, L.P. | 7.6% | SCHEDULE 13G/A |
| 2026-05-12 | Avidity Partners Management LP | 8.7% | SCHEDULE 13G/A |
| 2026-05-14 | Blue Owl Capital Holdings LP | 5.54% | SCHEDULE 13G/A |
| 2026-05-14 | Octagon Capital Advisors LP | 5.7% | SCHEDULE 13G |
| 2026-05-15 | Great Point Partners, LLC | 2.44% | SCHEDULE 13G/A |
| 2026-07-27 | BlackRock, Inc. | 6.7% | SCHEDULE 13G |
| 2026-07-31 | Octagon Capital Advisors LP | 3.3% | SCHEDULE 13G/A |
| 2026-08-12 | Blue Owl Capital Holdings LP | 3.19% | SCHEDULE 13G/A |
| 2026-08-14 | MPM BioImpact LLC | 1.4% | SCHEDULE 13G/A |
Questions about who owns Context Therapeutics Inc.
Who owns Context Therapeutics Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Context Therapeutics Inc.: Avidity Partners Management LP (8.7%, Schedule 13G/A, filed 2026-05-12), Soleus Capital Master Fund, L.P. (7.6%, Schedule 13G/A, filed 2026-05-08) and BlackRock, Inc. (6.7%, Schedule 13G, filed 2026-07-27).
Who are the largest shareholders of Context Therapeutics Inc.?
By the share each holder's latest filing reports, the largest holders of Context Therapeutics Inc. on this page are Avidity Partners Management LP (8.7%), Soleus Capital Master Fund, L.P. (7.6%) and BlackRock, Inc. (6.7%).
When did Avidity Partners Management LP buy into Context Therapeutics Inc.?
The filings give report dates, not purchase dates. The earliest filing from Avidity Partners Management LP on this page is the Schedule 13G/A, filed 2025-08-14, reporting 9.9%; its latest, Schedule 13G/A filed 2026-05-12, reports 8.7%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 16 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Context Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.